Pfizer Buying Spree Continues With $5.4B Hematology Deal

August 8, 2022by Tom Murphy and Michelle Chapman, Associated Press
Pfizer Buying Spree Continues With $5.4B Hematology Deal
The Pfizer logo is displayed on the exterior of a former Pfizer factory, on May 4, 2014, in Brooklyn, New York. (AP Photo/Mark Lennihan, File)

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease.

The latest deal follows Pfizer’s $11.6 billion acquisition of Biohaven, which the companies announced in May, and a $6.7 billion acquisition of Arena Pharmaceuticals announced last December.

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus.

Pfizer Inc.’s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition spree. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.

Pfizer’s vaccine, Comirnaty, rang up nearly $37 billion in sales last year alone, but those sales are expected to fade in a few years. Pfizer also faces over the next decade the loss of patent protection for key products like Eliquis for preventing blood clots and strokes.

The company plans to have about $25 billion in sales by 2030 come from new business developments.

Aamir Malik, the company’s chief business innovation officer, told analysts recently that Pfizer was “leaving very few stones unturned” in looking for expansion opportunities. Malik said Pifzer was looking for deals that will speed up growth in the back half of the decade and can add substantial value either scientifically or commercially.

“I think we’re very excited about the opportunities that are ahead of us and the flexibility that our balance sheet gives us to pursue those,” he said during a call to discuss second-quarter results.

Aside from Oxbryta, Global Blood Therapeutics also is developing some other treatments for sickle cell disease.

Oxbryta sales were about $195 million last year, but Pfizer said it plans to speed up distribution of the drug to parts of the world most impacted by the disease.

Sickle cell disease is an inherited blood disorder that can lead to bouts of acute pain and organ damage. It occurs particularly among people of African descent.

Pfizer will pay $68.50 per share in cash for each share of Global Blood Therapeutics. That represents a premium of nearly 43% from the stock’s closing price of $47.99 on Aug. 4, the day before The Wall Street Journal reported that Pfizer was in advanced talks on a deal.

Both companies’ boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders. The companies say the deal could close as soon as the fourth quarter.

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose more than 4% to $66.68 before the opening bell. Shares of Pfizer were essentially flat.

___

Follow Tom Murphy on Twitter: @thpmurphy

A+
a-
  • Pfizer
  • In The News

    Health

    Voting

    Business

    Amazon's Plans to Advance Its Interests in California Laid Bare in Leaked Memo

    NEW YORK (AP) — An internal Amazon memo has provided a stark look at the company’s carefully laid out plans... Read More

    NEW YORK (AP) — An internal Amazon memo has provided a stark look at the company’s carefully laid out plans to grow its influence in Southern California through a plethora of efforts that include burnishing its reputation through charity work and pushing back against “labor agitation”... Read More

    December 4, 2023
    by Dan McCue
    Justices Appear Divided Over Purdue Pharma Bankruptcy Deal

    WASHINGTON — The Supreme Court appeared divided on Monday over a bankruptcy deal struck by Purdue Pharma that would immunize... Read More

    WASHINGTON — The Supreme Court appeared divided on Monday over a bankruptcy deal struck by Purdue Pharma that would immunize the Sackler family, its one-time owners, from civil lawsuits for their role in the opioid crisis.  The closely watched case is considered to be among the most... Read More

    November 30, 2023
    by Dan McCue
    New York Appellate Court Reinstates Trump Gag Orders

    NEW YORK — A New York appeals court panel on Thursday reinstated a pair of gag orders issued in Donald... Read More

    NEW YORK — A New York appeals court panel on Thursday reinstated a pair of gag orders issued in Donald Trump’s civil fraud trial that barred the former president from speaking publicly about the judge’s court staff. The two-page decision by the New York State Supreme... Read More

    Mayo Clinic Announces $5B Expansion of Minnesota Campus

    MINNEAPOLIS (AP) — The Mayo Clinic announced a $5 billion expansion plan for its flagship campus Tuesday that includes new... Read More

    MINNEAPOLIS (AP) — The Mayo Clinic announced a $5 billion expansion plan for its flagship campus Tuesday that includes new buildings designed so they can evolve and expand as patient needs change over the coming decades. The project is part of a Mayo strategy to transform... Read More

    Broadcom Planning to Complete Deal for $69B Acquisition of VMWare After Regulators Give OK

    SAN JOSE, California (AP) — Computer chip and software maker Broadcom has announced it has cleared all regulatory hurdles and... Read More

    SAN JOSE, California (AP) — Computer chip and software maker Broadcom has announced it has cleared all regulatory hurdles and plans to complete its $69 billion acquisition of cloud technology company VMware on Wednesday. The company, based in San Jose, California, announced it planned to move... Read More

    November 15, 2023
    by Dan McCue
    Firm Drops Plans to Manufacture Offshore Wind Turbines in Virginia

    PORTSMOUTH, Va. — Siemens Gamesa, the German-Spanish wind engineering company, will not be building a planned $200 million factory to... Read More

    PORTSMOUTH, Va. — Siemens Gamesa, the German-Spanish wind engineering company, will not be building a planned $200 million factory to manufacture offshore wind turbine blades in Virginia after all. The massive facility, which had been projected to create more than 300 jobs, was a key component... Read More

    News From The Well
    scroll top